LONDON – Drone Guarder, Inc. (OTCQB:DRNG): Drone Guarder (DG) is pleased to announce negotiations for a strategic partnership to share commercial and technology platforms with a leading European drone technology company. The basis of our partnership will be a technology transfer between the two companies to enable DG to have industry leading technological functionality and streamlined delivery of the DG Drone to the market.
The key advantages to our pending arrangement includes new software innovations and enhanced range of applications. Specifically, we will develop ad hoc grid areas which have been surveyed by our DG Rescue Drone on the fly and then will be able to search any grid area whether a water body or terrain, in a real-time grid created by the tablet app. The drone will autonomously search the grid area during day or night time for survivors utilizing thermal and night vision cameras. Our proprietary technology allows the grid to be created flying in real time while streaming live images with the end user remotely viewing the search grid area.
Adam Taylor (CEO of DG) says we are very excited to be partnering with a leading European drone technology company for the synergy and advantages of sourcing new functionality and technology for the DG Drone. This will enable us to bring the world's most advance drone intruder and rescue products to the consumer, making DG a world leader in drone AI solutions. DG will be releasing details upon conclusion of negotiations and signing of a formal agreement.
About Drone Guarder Inc
DroneGuarder is an early stage security and surveillance company focusing on commercializing a drone enhanced home security system as a turnkey solution. The solution is app-based and includes a drone, infrared camera, and Android mobile app component: Once an alarm has been triggered, the DroneGuarderâ„¢ will immediately take off from a wireless charging pad.
Please visit www.droneguarder.com to learn about the company, management and products.
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.